Simcere Pharmaceutical Group ("Simcere" or the "Company") SCR, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced the resignation of Dr. Peng Wang, Chief Scientific Officer of the Company, effective from May 29, 2013. Dr. Wang resigned for personal reasons. His resignation has been approved by the Company.
Mr. Hongquan Liu, the Chief Executive Officer of Simcere, said, "We thank Dr. Wang for his contribution to our research and development efforts and we wish him all the best in the future."
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group ("Simcere" or the "Company") SCR is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases, and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.
Investor and Media Contacts:
Email: ir@simcere.com
In Nanjing:
Jie Liu D'Elia
Vice President
Simcere Pharmaceutical Group
Tel: 86-25-8556-6666*8857
In the United States:
Cindy Zheng
Brunswick Group LLC
Tel: 1-212-333-3810
In Beijing:
Yue Yu
Brunswick
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in